Assessment of Enterococcus faecalis biofilm response to amoxicillin and ciprofloxacin using a dynamic in vitro pharmacokinetic-pharmacodynamic model of catheter-associated urinary tract infection
Abstract
Background: Catheter-associated urinary tract infections (CAUTIs) are among the most common types of healthcare-associated infections. Among uropathogens, Enterococcus faecalis is particularly notable for its strong capacity to form biofilms on urinary catheters, thereby decreasing its susceptibility to antibiotics commonly used to treat CAUTIs. However, current antibiotic dosing strategies still rely on planktonic phenotypes, limiting their applicability to biofilm-associated infections. To address this limitation, a dynamic in vitro pharmacokinetic-pharmacodynamic model was developed to assess E. faecalis biofilms' response to different treatment regimens.
Methods: Biofilms of model E. faecalis strains (ATCC 29212 and 54) were preformed on urinary catheters. Mature biofilms were subjected to simulated urinary dosing regimens of amoxicillin (500 mg q12h for 3 days) or ciprofloxacin (500 mg q24h for 3 days), as well as to constant antibiotic concentrations for 3 days. Viable bacterial counts and biofilm biomass were then measured at predefined timepoints, and the effects of the simulated dosing regimens were compared to those observed under constant antibiotic exposure.
Results: Our findings indicate that daily ciprofloxacin demonstrated the greatest antibacterial activity, significantly surpassing the effects of constant ciprofloxacin exposure, twice-daily dosing of amoxicillin, and constant amoxicillin exposure. Although the simulated amoxicillin regimen was more effective…
Read the paper
Related studies
- Horizontal gene transfer in the human gastrointestinal tract: potential spread of antibiotic resistance genes
- Mutation supply and relative fitness shape the genotypes of ciprofloxacin-resistant Escherichia coli
- Genomic Survey of E. coli From the Bladders of Women With and Without Lower Urinary Tract Symptoms
- Characterization of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017–18
- Fitness cost constrains the spectrum of marR mutations in ciprofloxacin-resistant Escherichia coli
- Emerging evidence-based innovative approaches to control catheter-associated urinary tract infection: a review
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.